Literature DB >> 21419541

Postoperative follow-up strategy in patients with oral squamous cell carcinoma.

Masashi Sasaki1, Takayuki Aoki, Kazunari Karakida, Mitsunobu Otsuru, Miho Takahashi, Tadashi Akamatsu, Haruo Sakamoto, Yoshihide Ota.   

Abstract

PURPOSE: The duration of follow-up after treatment of oral squamous cell carcinoma and the frequency of routine visits are based on common usage rather than evidence-based practice. The purpose of this study was to determine the appropriate postoperative routine follow-up program in patients with oral squamous cell carcinoma. PATIENTS AND METHODS: Three hundred four cases treated curatively mainly by surgery at Tokai University Hospital from 1994 to 2004 were analyzed. A secondary event was defined as a local recurrence, a regional recurrence, a distant metastasis, or a second primary cancer. To evaluate the follow-up program, data on the first tumor recurrence or first second primary tumor in the head and neck region or elsewhere in the body were used. Overall survival rate, disease-specific survival rate, relapse-free rate, and cumulative risk of developing a second primary cancer were estimated by the Kaplan-Meier product limit method. RESULT: All relapse cases were detected within 3 years postoperatively, of which 86.3% were detected within 1 year. Most relapses were in the neck, and regional recurrences had a dismal salvage rate. Second primary cancers were constantly detected 1 to 10 years postoperatively.
CONCLUSION: Follow-up should be performed more frequently in the first year, with 2 weekly follow-ups with monthly ultrasound examinations, and should be continued after 3 years to exclude the development of second primary cancers.
Copyright © 2011 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21419541     DOI: 10.1016/j.joms.2010.11.039

Source DB:  PubMed          Journal:  J Oral Maxillofac Surg        ISSN: 0278-2391            Impact factor:   1.895


  7 in total

1.  Closure of defects after resection of tumors of the oral cavity and the pharynx: medium- to long-term oncologic and functional results with the myocutaneous platysma flap.

Authors:  Julian Künzel; Heinrich Iro; Georgios Psychogios; Johannes Zenk; Michael Koch
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-02-09       Impact factor: 2.503

2.  Outcomes after up-front surgery and metronomic neoadjuvant chemotherapy with S-1 or UFT for early tongue squamous cell carcinoma.

Authors:  Shinichiro Kina; Toshiyuki Nakasone; Takao Kinjo; Fumikazu Nimura; Nao Sunagawa; Akira Arasaki
Journal:  Clin Oral Investig       Date:  2018-10-13       Impact factor: 3.573

Review 3.  Post-therapeutic surveillance schedule for oral cancer: is there agreement?

Authors:  Guicai Liu; Eric J Dierks; R Bryan Bell; Tuan G Bui; Bryce E Potter
Journal:  Oral Maxillofac Surg       Date:  2012-09-02

4.  Association of cytokeratin 17 expression with differentiation in oral squamous cell carcinoma.

Authors:  Ryoji Kitamura; Takeshi Toyoshima; Hideaki Tanaka; Shintaro Kawano; Takahiro Kiyosue; Ryota Matsubara; Yuichi Goto; Mitsuhiro Hirano; Kazunari Oobu; Seiji Nakamura
Journal:  J Cancer Res Clin Oncol       Date:  2012-04-03       Impact factor: 4.553

5.  Cytokeratin 17 mRNA as a prognostic marker of oral squamous cell carcinoma.

Authors:  Ryoji Kitamura; Takeshi Toyoshima; Hideaki Tanaka; Shintaro Kawano; Ryota Matsubara; Yuichi Goto; Teppei Jinno; Yasuyuki Maruse; Kazunari Oobu; Seiji Nakamura
Journal:  Oncol Lett       Date:  2017-09-26       Impact factor: 2.967

6.  Time patterns of recurrence and second primary tumors in a large cohort of patients treated for oral cavity cancer.

Authors:  Maria T Brands; Elisabeth A J Smeekens; Robert P Takes; Johannes H A M Kaanders; Andre L M Verbeek; Matthias A W Merkx; Sandra M E Geurts
Journal:  Cancer Med       Date:  2019-08-10       Impact factor: 4.452

7.  Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4.

Authors:  Shinji Yamada; Shunsuke Itai; Mika K Kaneko; Yukinari Kato
Journal:  Biochem Biophys Rep       Date:  2018-02-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.